Targeted investigational therapy shows early promise against multiple cancer types
The investigational, oral drug BGJ398, which blocks the activity of a family of proteins called fibroblast growth factor receptors (FGFRs), showed promising anticancer activity in patients with various types of cancer driven ...
Apr 9, 2014
0
0